Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Typically days to weeks, varying by insurer, documentation completeness, and appeal necessity
Our program brings together the benefits of cutting-edge medication with the vital support necessary for GLP-1 behavior changes to stick
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
revenue and Mounjaro and Zepbound (tirzepatide) 48% of Eli Lillys, highlighting the unprecedented speed of adoption and market dominance of these four drugs
By Route of Administration, Parenteral dominated with the largest share in 2025
US$ 27.28
US$ 20.77
US$ 23.21
US$ 23.11
US$ 24.22
US$ 23.22
US$ 22.23
